If you are also taking insulin or a sulfonylurea, be aware that adding any incretin-based therapy may increase the risk of hypoglycaemia
This combined approach results in improved glycemic control and significant weight reduction
Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: A scientific statement from the American Heart Association
Currently, this treatment remains in clinical development and is not yet available to buy
Retatrutide is often referred to as a triple-agonist metabolic therapy because it activates three key metabolic hormones at once: GLP-1 GIP Glucagon This triple mechanism may produce stronger metabolic effects than current medications like Mounjaro, Ozempic, or Semaglutide
If you or your weight management doctor raise concerns about side effects, ask about ways to minimize them, such as starting with a lower dose or adjusting your diet